Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.